MapLight Therapeutics, Inc.
No enriched coverage for $MPLT in the last 7 days.
Catalyst4, Inc. purchased 1,209,225 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at an average of $12.66 ($10.74–$13.00, $15.31M total) across 4 trades over 2026-07-28 to 2026-07-30.
Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
Stocks slipped from early highs as chipmakers and AI-infrastructure shares fell. The iShares Semiconductor ETF (SOXX) fell over 3%, with Sandisk (SNDK) down more than 11% and AMD and Western Digital down over 6%. Crude dropped about 6%, lifting T-notes and lowering 10-year breakeven inflation. Software stocks rose; Workday gained over 8%.
Recent MPLT coverage spans insider activity, market movers and earnings.
In the last 30 days, MPLT insiders filed 50 SEC Form 4 transactions — 5 purchases ($15.5M) and 45 sales ($11.5M). The most active reporter was Foff Erin Pennock, Chief Medical Officer, with 9 filings. 48% of activity was filed under pre-arranged Rule 10b5-1 plans.
A 10% owner indirect open-market purchase is a bullish signal, but it is not a fundamental catalyst like guidance, trial data, or a deal.
The rebound appears to be a technical and narrative reset after mixed efficacy, with FDA discussion as the next decision point.
MPLT has a high-conviction negative catalyst from trial readout underperforming expectations.
The disclosed director buy is a modest, sentiment-supportive signal, but it does not change the fundamental clinical-trial narrative described.
This is an insider buy disclosure, but it is not a fundamental catalyst by itself.
alphai scores every news story that mentions MPLT with an AI model for sentiment and relevance, and aggregates insider trades from MapLight Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Catalyst4, Inc. purchased 1,209,225 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at an average of $12.66 ($10.74–$13.00, $15.31M total) across 4 trades over 2026-07-28 to 2026-07-30.
2 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readStocks slipped from early highs as chipmakers and AI-infrastructure shares fell. The iShares Semiconductor ETF (SOXX) fell over 3%, with Sandisk (SNDK) down more than 11% and AMD and Western Digital down over 6%. Crude dropped about 6%, lifting T-notes and lowering 10-year breakeven inflation. Software stocks rose; Workday gained over 8%.
6 min readMapLight Therapeutics director Troy Cox bought 15,620 shares of MPLT for $148,702 on July 28, 2026, at a weighted average price of $9.52. The stock later traded around $12.31. The article also notes multiple analyst price target cuts and rating changes tied to MapLight’s Phase 2 ZEPHYR trial results.
3 min readCox Troy purchased 15,620 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $9.52 ($0.15M total) on 2026-07-28.
1 min readMapLight Therapeutics shares fell 71.9% after it reported mixed Phase II schizophrenia trial data, dropping from $35.23 (July 23 close) to $9.90 (July 27 close). The Nasdaq-listed company raised $250m in an Oct 2025 IPO for its ZEPHYR trial. MapLight aims to compete with BMS’s Cobenfy, which GlobalData projects could reach $2.2bn in 2031.
4 min readMapLight Therapeutics (MPLT) reported mixed topline Phase 2 ZEPHYR schizophrenia results. The 210/3 mg twice-daily dose met the primary PANSS improvement endpoint (effect size 0.37 mITT, p=0.002; 0.50 completers, p=0.002). The 330/6 mg once-daily arm was not statistically significant. Company said cognition improved in impaired patients (effect size 0.51, p=0.041). Shares fell.
4 min readOil fell after a lull in Middle East hostilities and a US pause in strikes against Iran, with September Brent down about 9% to around $88 per barrel. Bond yields and the dollar eased, while US stock futures rose on a relief rally. The article also cites premarket moves in several stocks, including QBTS, F, FBRX, GM, GOSS, and MPLT, plus Argenx buying Forte Biosciences for about $2.2B.
7 min readMapLight Therapeutics (NASDAQ:MPLT) shares fell about 40% after topline Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia. The 210/3 mg twice-daily dose met the primary PANSS endpoint at Week 5 versus placebo, while the 330/6 mg once-daily dose did not. The twice-daily arm also showed significant secondary endpoints; safety was generally tolerable. The company plans an FDA End-of-Phase 2 meeting.
3 min readGILLIS JONATHAN (CAO and Interim CFO) sold 36,979 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $37.12 ($36.13–$38.17, $1.37M total) across 7 trades over 2026-07-15 to 2026-07-17 under a Rule 10b5-1 trading plan.
2 min read
